Erste Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Erste Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$382K	Hold	40,000	–	–	﹤0.01%	537
2026 Q1	$378K	Hold	40,000	–	–	﹤0.01%	533
2025 Q4	$308K	Hold	40,000	–	–	﹤0.01%	538
2025 Q3	$302K	Hold	40,000	–	–	﹤0.01%	531
2025 Q2	$374K	Hold	40,000	–	–	﹤0.01%	675
2025 Q1	$314K	Hold	40,000	–	–	﹤0.01%	458
2024 Q4	$308K	Hold	40,000	–	–	﹤0.01%	470
2024 Q3	$305K	Hold	40,000	–	–	﹤0.01%	467
2024 Q2	$244K	Hold	40,000	–	–	﹤0.01%	469
2024 Q1	$206K	Hold	40,000	–	–	﹤0.01%	473
2023 Q4	$244K	Hold	40,000	–	–	﹤0.01%	475
2023 Q3	$290K	Hold	40,000	–	–	0.01%	454
2023 Q2	$278K	Hold	40,000	–	–	﹤0.01%	464
2023 Q1	$336K	Hold	40,000	–	–	0.01%	463
2022 Q4	$447K	Hold	40,000	–	–	0.01%	434
2022 Q3	$494K	Hold	40,000	–	–	0.01%	424
2022 Q2	$432K	Hold	40,000	–	–	0.01%	446
2022 Q1	$658K	Buy	+40,000	New	+$642K	0.01%	409

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Erste Asset Management's BCRX Position: Q2 2026 in Review

Erste Asset Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 40,000 shares worth $382K. The position accounts for ﹤0.01% of the portfolio, ranked #537.

Erste Asset Management first reported a position in BCRX in Q1 2022 and has held it in 18 quarters since. The position peaked at $658K in Q1 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Erste Asset Management held 40,000 shares of BioCryst Pharmaceuticals worth $382K as of Q2 2026.
Erste Asset Management left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Erste Asset Management's portfolio in Q2 2026, its #537 holding.
Erste Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
Erste Asset Management's BioCryst Pharmaceuticals position peaked at $658K in Q1 2022.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.